References
- Bichi R, Shinton SA, Martin ES, Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002;99:6955–6960.
- Klein U, Lia M, Crespo M, The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010;17: 28–40.
- Herling M, Patel KA, Weit N, High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood 2009;114: 4675–4686.
- Herling M, Patel KA, Khalili J, TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia 2006;20:280–285.
- Hoyer KK, Herling M, Bagrintseva K, T cell leukemia-1 modulates TCR signal strength and IFN-gamma levels through phosphatidylinositol 3-kinase and protein kinase C pathway activation. J Immunol 2005;175:864–873.
- Herling M, Patel KA, Hsi ED, TCL1 in B-cell tumors retains its normal B-cell pattern of regulation and is a marker of differentiation stage. Am J Surg Pathol 2007;31: 1123–1129.
- Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 2000;6:395–407.
- Kunstle G, Laine J, Pierron G, Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1. Mol Cell Biol 2002;22:1513–1525.
- Herling M, Patel KA, Teitell MA, High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood 2008;111:328–337.
- Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627–644.
- Quiroga MP, Balakrishnan K, Kurtova AV, B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009;114:1029–1037.
- Lerner A, Kim DH, Lee R. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. Leuk Lymphoma 2000;37:39–51.
- Kuraishy AI, French SW, Sherman M, TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation. Proc Natl Acad Sci USA 2007;104:10175–10180.
- Misra UK, Kaczowka SJ, Pizzo SV. Interaction between TCL1 and Epac1 in the activation of Akt kinases in plasma membranes and nuclei of 8-CPT-2-O-Me-cAMP-stimulated macrophages. Cell Signal 2008;20:130–138.
- Pekarsky Y, Palamarchuk A, Maximov V, TCL1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci USA 2008;105:19643–19648.
- Ropars V, Despouy G, Stern MH, Benichou S, Roumestand C, Arold ST. The TCL1A oncoprotein interacts directly with the NF-kappaB inhibitor IkappaB. PLoS One 2009;4: e6567.